Cervical And Vaginal/Vulvar Malignancies Risk In Women With Rheumatoid Arthritis (RA)
DOI:
https://doi.org/10.12970/2310-9874.2018.06.05Keywords:
Rheumatoid arthritis, cervical cancer, vaginal cancer, vulvar cancerAbstract
Objective: Given recent concerns about cervical dysplasia with RA medications, we performed a literature review and a pooled analysis to examine the relative risk of cervical and vaginal cancers in RA.
Methods: We conducted a literature search covering 2007- 2014. A pooled analysis was conducted: the total numbers of cancers expected and observed across all studies were respectively summed for different cancer types (cervical and vaginal/vulvar cancers). As some studies pooled vaginal and vulvar cancers together, we did not discern between the two for the purpose of this study. Using these pooled estimates, standardized incidence ratios (SIRs) were calculated, demonstrating the relative risk of the cancers in RA, versus the general population.
Results: Our search strategy retrieved 13 papers. Our pooled SIR estimates were 0.82, 95% confidence interval, CI, 0.73-0.92 for cervical cancer in RA and 1.04, 95% CI 0.80-1.34 for vaginal/vulvar cancer in RA.
Conclusion: Our simple pooled analysis was consistent with a relatively lower cervical cancer risk in RA versus the general population, while the data did not establish if the risk of vaginal/vulvar cancer was different from the general population. Cervical cancer screening in RA will continue to be important, particularly as evolving treatment strategies may affect future risk.
References
Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61. https://doi.org/10.1038/nature01661
Bansback N, Marra CA, Finckh A, Anis A. The economics of treatment in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009; 23: 83-92. https://doi.org/10.1016/j.berh.2008.11.005
Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 2015; 17: 212. https://doi.org/10.1186/s13075-015-0728-9
Wilton KM, Matteson EL. Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis. Rheumatol Ther 2017; 4(2): 333-347. https://doi.org/10.1007/s40744-017-0064-4
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86. https://doi.org/10.1002/ijc.29210
Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet 2013; 382(9895): 889-99. https://doi.org/10.1016/S0140-6736(13)60022-7
Furlan AD, Irvin E, Bombardier C. Limited search strategies were effective in finding relevant nonrandomized studies. J Clin Epidemiol 2006; 59: 1303-11. https://doi.org/10.1016/j.jclinepi.2006.03.004
Breslow NE, Day NE. Statistical methods in cancer research, Volume II-The design and analysis of cohort studies. IARC Sci Publ 1987: 1-406.
Abásolo L, Júdez E, Descalzo MA, González-Alvaro I, Jover JA, Carmona L, et al. Cancer in rheumatoid arthritis: Occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 2008; 37: 388-97. https://doi.org/10.1016/j.semarthrit.2007.08.006
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-6. https://doi.org/10.1136/ard.2004.033993
Chen YJ, Chang YT, Wang CB, Wu CY. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum 2011; 63: 352-8. https://doi.org/10.1002/art.30134
Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997; 40: 1580-6. https://doi.org/10.1002/art.1780400906
Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307-11. https://doi.org/10.1093/jnci/85.4.307
Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology 2008; 47: 698-701. https://doi.org/10.1093/rheumatology/ken130
Hemminki K, Liu X, Ji J, Försti A, Sundquist J, Sundquist K. Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol 2012; 127: 180-5. https://doi.org/10.1016/j.ygyno.2012.07.100
Huang WK, Chiou MJ, Kuo CF, Lin YC, Yu KH, See LC. No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan. Rheumatol Int 2014; 34: 1379-86. https://doi.org/10.1007/s00296-014-2982-6
Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32: 1753-7. https://doi.org/10.1016/0959-8049(96)00210-9
Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology 2013; 52: 91-8. https://doi.org/10.1093/rheumatology/kes350
Moritomo H, Ueda T, Hiyama T, Hosono N, Mori S, Komatsubara Y. The risk of cancer in rheumatoid patients in Japan. Scand J Rheumatol 1995; 24: 157-9. https://doi.org/10.3109/03009749509099305
Parikh-Patel A, White RH, Allen M, Cress R. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 2009; 20: 1001-10. https://doi.org/10.1007/s10552-009-9298-y
Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497-502. https://doi.org/10.1002/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J
Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95. https://doi.org/10.1002/art.22864
Yamada T, Nakajima A, Inoue E, Tanaka E, Taniguchi A, Momohara S. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int 2011; 31: 1487-92. https://doi.org/10.1007/s00296-010-1524-0
Clarke MA, Rodriguez AC, Gage JC, Herrero R, Hildesheim A, Wacholder S, Burk R, Schiffman M. A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infect Dis 2012; 12: 33. https://doi.org/10.1186/1471-2334-12-33
Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006; 108: 1361-8. https://doi.org/10.1097/01.AOG.0000245786.86267.80
Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus‐induced malignancies in systemic lupus erythematosus: A long‐term followup study in a Danish cohort. Arthritis Rheum 2011; 63: 3032-7. https://doi.org/10.1002/art.30483
Feldman CH, Liu J, Feldman S, Solomon DH, Kim SC. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. Lupus 2017; 26(7): 682-689. https://doi.org/10.1177/0961203316672928
Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancy in systemic lupus erythematosus: what have we learned? Best Pract Res Clin Rheumatol 2009; 23: 539-47. https://doi.org/10.1016/j.berh.2008.12.007
Goobie GC, Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol 2015; 27(5): 454-60. https://doi.org/10.1097/BOR.0000000000000202
Wadström H, Frisell T, Sparén P, Askling J, Klareskog L, Lindblad S, et al. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.Ann Rheum Dis. 2016; 75: 1272-8. https://doi.org/10.1136/annrheumdis-2015-208263
Rojo-Contreras W, Olivas-Flores EM, Gamez-Nava JI, Montoya-Fuentes H, Trujillo-Hernandez B, Trujillo X. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus 2012; 21: 365-72. https://doi.org/10.1177/0961203311425517
Kim SY, Schneeweiss S, Meyers JE, Liu J, Solomon DH. Cancer Screening Rates in Patients with Rheumatoid Arthritis: No Different Than the General Population. Arthritis Rheum 2012; 64: 3076-3082. https://doi.org/10.1002/art.34542
Tessier-Cloutier B, Clarke AE, Pineau CA, Keeling S, Bissonauth A, Ramsey-Goldman R. What investigations are needed to optimally monitor for malignancies in SLE? Lupus 2015; 24: 781-7. https://doi.org/10.1177/0961203315575587
